{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T22:23:51Z","timestamp":1707431031744},"reference-count":44,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>With the advent new proteasome inhibitors (carfilzomib, ixazomib), new immune-modulatory drugs (pomalidomide), and new monoclonal antibodies (elotuzimab, daratumumab) as approved treatments for myeloma, the therapeutic landscape for this disease has changed. In this chapter, using a case-based approach, I will provide a personal guide of how I approach myeloma therapy in a transplant eligible patient in 2018.<\/jats:p>","DOI":"10.1182\/asheducation-2018.1.103","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T18:13:59Z","timestamp":1555438439000},"page":"103-109","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients"],"prefix":"10.1182","volume":"2018","author":[{"given":"Sergio","family":"Giralt","sequence":"first","affiliation":[{"name":"Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Seifter","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"26","key":"2019111521552571900_B1","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111521552571900_B2","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"2019111521552571900_B3","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1200\/JCO.2014.57.9961","article-title":"Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement","volume":"33","author":"Dimopoulos","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111521552571900_B4","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"issue":"13","key":"2019111521552571900_B5","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2017-05-743203","article-title":"How I treat myeloma with new agents","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"issue":"10068","key":"2019111521552571900_B6","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"21","key":"2019111521552571900_B7","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2019111521552571900_B8","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.bbmt.2016.11.011","article-title":"Maintenance versus induction therapy choice on outcomes after autologous transplantation for multiple myeloma","volume":"23","author":"Cornell","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2019111521552571900_B9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/bmt.2016.214","article-title":"The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents","volume":"52","author":"Chakraborty","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2019111521552571900_B10","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"issue":"22","key":"2019111521552571900_B11","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1182\/blood.V128.22.675.675","article-title":"Final results of a phase 2 trial of extended treatment (tx) with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (KRd) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM) [abstract]","volume":"128","author":"Zimmerman","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2019111521552571900_B12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.6004\/jnccn.2018.0002","article-title":"NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018","volume":"16","author":"Kumar","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"2019111521552571900_B13","unstructured":"Intergroupe Francophone du Myelome. A study to evaluate daratumumab in transplant eligible participants with previously untreated multiple myeloma (Cassiopeia). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02541383. Accessed 20 December 2017."},{"issue":"6","key":"2019111521552571900_B14","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2019111521552571900_B15","first-page":"1879","article-title":"Griffin interim safety analysis of a phase 2 randomized study of daratumumab (Dara), lenalidomide (R), bortezomib (V), and dexamethasone (d; Dara-Rvd) vs. Rvd in patients (Pts) with newly diagnosed multiple myeloma (MM) eligible for high\u2010dose therapy (HDT) and autologous stem cell transplantation (ASCT) [abstract]","volume":"130","author":"Voorhees","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111521552571900_B16","first-page":"3110","article-title":"Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma (MMY1001): updated results from an open-label, phase 1b study [abstract]","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2019111521552571900_B17","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/leu.2015.209","article-title":"Defining and treating high-risk multiple myeloma","volume":"29","author":"Usmani","year":"2015","journal-title":"Leukemia"},{"issue":"13","key":"2019111521552571900_B18","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111521552571900_B19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/bjh.15244","article-title":"Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation","volume":"182","author":"Chakraborty","year":"2018","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111521552571900_B20","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbmt.2014.10.023","article-title":"Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma","volume":"21","author":"Vij","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 1","key":"2019111521552571900_B21","first-page":"397","article-title":"Autologous stem cell transplantation versus bortezomib-melphalan-prednisone for newly diagnosed multiple myeloma: second interim analysis of the phase 3 EMN02\/HO95 study [abstract]","volume":"130","author":"Cavo","year":"2017","journal-title":"Blood"},{"issue":"14","key":"2019111521552571900_B22","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111521552571900_B23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"issue":"4","key":"2019111521552571900_B24","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.bbmt.2014.12.024","article-title":"Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma","volume":"21","author":"Costa","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"2019111521552571900_B25","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1002\/cncr.30747","article-title":"Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report","volume":"123","author":"Schriber","year":"2017","journal-title":"Cancer"},{"issue":"22","key":"2019111521552571900_B26","doi-asserted-by":"crossref","first-page":"LBA-1","DOI":"10.1182\/blood.V128.22.LBA-1.LBA-1","article-title":"Comparison of autologous hematopoietic cell transplant (autoHCT), bortezomib, lenalidomide (len) and dexamethasone (RVD) consolidation with len maintenance (ACM), tandem autohct with len Maintenance (TAM) and autohct with len maintenance (AM) for up-front treatment of patients with multiple myeloma (MM): primary results from the randomized phase III trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 \u2013 StaMINA Trial) [abstract]","volume":"128","author":"Stadtmauer","year":"2016","journal-title":"Blood"},{"issue":"29","key":"2019111521552571900_B27","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111521552571900_B28","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1182\/blood-2014-06-583302","article-title":"Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment","volume":"124","author":"Pawlyn","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111521552571900_B29","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/leu.2013.335","article-title":"Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients","volume":"28","author":"Nooka","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"2019111521552571900_B30","first-page":"609","article-title":"Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry","volume":"87","author":"Alegre","year":"2002","journal-title":"Haematologica"},{"issue":"2","key":"2019111521552571900_B31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clml.2016.11.010","article-title":"Practical considerations in managing relapsed multiple myeloma","volume":"17","author":"Agarwal","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"2019111521552571900_B32","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"issue":"14","key":"2019111521552571900_B33","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111521552571900_B34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.clml.2017.12.011","article-title":"A comparison of the efficacy of immunomodulatory-containing regimens in relapsed and refractory multiple myeloma: a network meta-analysis","volume":"18","author":"Dimopoulos","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2019111521552571900_B35","first-page":"480","article-title":"Comparative efficacy of treatments for previously treated multiple myeloma: a systematic literature review and network meta-analysis","author":"Maiese","year":"2018"},{"issue":"7","key":"2019111521552571900_B36","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/bloodadvances.2016003905","article-title":"Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed\/refractory patients","volume":"1","author":"Botta","year":"2017","journal-title":"Blood Adv"},{"key":"2019111521552571900_B37","article-title":"Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: evaluation of results from 102 clinical trials [published online ahead of print 19 April 2018]","author":"Mangal","journal-title":"Hematol Oncol"},{"issue":"10","key":"2019111521552571900_B38","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1038\/leu.2016.101","article-title":"Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party","volume":"30","author":"Sobh","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"2019111521552571900_B39","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2018.04.018","article-title":"Long-term results of prophylactic donor lymphocyte infusions for patients with multiple myeloa after allogeneic stem cell transplantation","volume":"24","author":"Gr\u00f6ger","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2019111521552571900_B40","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.bbmt.2018.03.012","article-title":"The role of allogeneic transplantation for multiple myeloma in the era of novel agents: a study from the Japanese Society of Myeloma","volume":"24","author":"Kawamura","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2019111521552571900_B41","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bbmt.2017.10.014","article-title":"Long-term follow-up of a donor versus no-donor comparison in patients with multiple myeloma in first relapse after failing autologous transplantation","volume":"24","author":"Patriarca","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111521552571900_B42","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.bbmt.2017.10.024","article-title":"Autologous\/allogeneic hematopoietic cell transplantation versus tandem autologous transplantation for multiple myeloma: comparison of long-term postrelapse survival","volume":"24","author":"Htut","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2019111521552571900_B43","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.bbmt.2015.09.016","article-title":"American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma","volume":"21","author":"Giralt","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2019111521552571900_B44","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1080\/10428194.2017.1393668","article-title":"CAR T cell therapy for multiple myeloma: where are we now and where are we headed?","volume":"59","author":"Ghosh","year":"2018","journal-title":"Leuk Lymphoma"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/103\/1254221\/hem01814.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/103\/1254221\/hem01814.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T23:58:26Z","timestamp":1573862306000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2018\/1\/103\/277609\/Casebased-roundtable-on-treatment-approach-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,11,30]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2018.1.103","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,30]]}}}